AIM2 and leukemia: Together, the results demonstrated that ATRA+MRT treatment can activate the AIM2 inflammasome-caspase-1 pathway to inhibit p21 proteasomal degradation, promoting myeloid differentiation and cell growth arrest in leukemia cells.